Coherus Oncology, Inc.
CHRS
$1.60
$0.020.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.85% | 91.19% | -0.41% | 229.25% | -91.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.85% | 91.19% | -0.41% | 229.25% | -91.55% |
| Cost of Revenue | 47.09% | 36.35% | 87.67% | 84.36% | -96.75% |
| Gross Profit | 74.65% | 136.23% | -19.18% | 469.16% | -28.37% |
| SG&A Expenses | -29.04% | -18.83% | -5.36% | -12.17% | -37.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.48% | 1.69% | 11.65% | -10.86% | -65.72% |
| Operating Income | 4.64% | 9.87% | -14.79% | 20.55% | 28.42% |
| Income Before Tax | -0.55% | 6.47% | 18.21% | 30.33% | 42.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.55% | 6.47% | 18.21% | 30.33% | 42.13% |
| Earnings from Discontinued Operations | 289.09% | -75.61% | 717.15% | -105.37% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.75% | -230.49% | 2,404.52% | -154.99% | 36.35% |
| EBIT | 4.64% | 9.87% | -14.79% | 20.55% | 28.42% |
| EBITDA | 4.44% | 8.92% | -15.69% | 20.28% | 28.86% |
| EPS Basic | 28.80% | -227.65% | 2,380.18% | -153.52% | 38.52% |
| Normalized Basic EPS | 9.01% | 11.66% | -5.13% | 19.69% | 39.96% |
| EPS Diluted | 28.80% | -227.65% | 2,380.18% | -153.52% | 38.96% |
| Normalized Diluted EPS | 9.01% | 11.66% | -5.13% | 19.69% | 39.96% |
| Average Basic Shares Outstanding | 4.29% | 0.88% | 1.10% | 2.76% | 3.52% |
| Average Diluted Shares Outstanding | 4.29% | 0.88% | 1.10% | 2.76% | 3.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |